Evidence map›Paper›PMID 17174637›Full record

ArticleAmerican heart journal2007

Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.

Anke-Hilse Maitland-van der Zee, Eric Boerwinkle, Donna K Arnett, Barry R Davis, Catherine Leiendecker-Foster, Michael B Miller, Olaf H Klungel, Charles E Ford, John H Eckfeldt

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00563901 (GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00563901 completednot on this map

GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT

TypeobservationalSponsorUniversity of Alabama at BirminghamRan2000 to 2004Enrolled37,939ConditionsHypertension, Coronary Disease, Cerebrovascular Accident
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Gene-drug interaction in stroke.Stroke research and treatment · 2011
    Article
  8. Pharmacogenetics of cardiovascular drug therapy.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2009
    Article
  9. ACE genotype, risk and causal relationship to stroke: implications for treatment.Current treatment options in cardiovascular medicine · 2007
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Anke-Hilse Maitland-van der ZeeSchool of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA. a.h.maitland@pharm.uu.nl
Eric Boerwinkle
Donna K Arnett
Barry R Davis
Catherine Leiendecker-Foster
Michael B Miller
Olaf H Klungel
Charles E Ford
John H Eckfeldt
The University of Texas Health Science Center at Houston · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USUtrecht University · NL

Funding

GENHAT-GENETICS OF HYPERTENSION ASSOCIATED TREATMENTSR01HL063082 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ARNETT, DONNA K · 1999 to 2009
$5.1M
Genetics of Hypertension Associated Treatment "GenHAT"R01HL083498 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BOERWINKLE, ERIC A. · 2007 to 2009
$1.4M
NHLBI NIH HHS R01 HL063082NHLBI NIH HHS R01 HL083498
6 · The paper itself

Abstract

backgroundThe aim of this study was to determine whether the angiotensin-converting enzyme (ACE) insertion-deletion (ID) polymorphism interacts with pravastatin to modify the risk of coronary heart disease (CHD) and other cardiovascular end points in a large clinical trial.

methodsGenHAT is an ancillary study of the ALLHAT. The ACE ID genotyped population in the lipid-lowering arm of ALLHAT included 9467 participants randomly assigned to pravastatin (n = 4741) or to usual care (n = 4726). The efficacy of pravastatin in reducing the risk of primary outcome (all-cause mortality) and secondary outcomes (fatal CHD and nonfatal myocardial infarction, cardiovascular disease [CVD] mortality, CHD, stroke, other CVD, non-CVD mortality, stroke, and heart failure) was compared between the genotype strata (dominant model ID + II vs DD, additive model II vs ID vs DD), by examining an interaction term in a Cox proportional hazards model.

resultsThe relative risk of fatal CHD and nonfatal myocardial infarction among subjects randomized to pravastatin compared with subjects randomized to usual care was similar in subjects with the II genotype (hazard ratio [HR] 0.84, 95% CI 0.59-1.18), the ID genotype (HR 0.84, 95% CI 0.68-1.03), and the DD genotype (HR 0.99, 95% CI 0.77-1.27).

conclusionsWe found no evidence that the ACE ID genotype was a major modifier of the efficacy of pravastatin in reducing the risk of cardiovascular events.

Indexed as

AgedAntihypertensive AgentsCoronary DiseaseFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMaleMiddle AgedMyocardial InfarctionPeptidyl-Dipeptidase APharmacogeneticsPolymorphism, GeneticPravastatinProportional Hazards ModelsRandomized Controlled Trials as TopicAntihypertensive AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPeptidyl-Dipeptidase APravastatin

Identifiers

PMID17174637
PMCPMC2766552
OpenAlexW2148736442

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.